N10 Wealth LLC Acquires 862 Shares of Eli Lilly and Company $LLY

Key Points

• N10 Wealth increased its Eli Lilly stake by 21% in the third quarter, adding 862 shares to hold 4,973 shares worth approximately $5.75 million. Institutional investors collectively own 82.53% of the company.
• Analysts remain broadly optimistic, with a “Moderate Buy” consensus and an average price target of $1,313.43. Eli Lilly recently exceeded earnings and revenue expectations, reporting $8.38 in EPS and $22.97 billion in quarterly revenue, up 47.7% year over year.
• Shares opened at $1,211.08, near their 12-month high, but valuation remains elevated at roughly 40.6 times earnings. Insiders sold 13,500 shares worth about $15.96 million during the quarter, while investors continue to monitor obesity-drug growth and pipeline developments.

N10 Wealth LLC boosted its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 21.0% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 4,973 shares of the company's stock after acquiring an additional 862 shares during the quarter. Eli Lilly and Company accounts for approximately 1.6% of N10 Wealth LLC's investment portfolio, making the stock its 21st biggest holding. N10 Wealth LLC's holdings in Eli Lilly and Company were worth $5,754,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the stock. Osbon Capital Management LLC purchased a new stake in shares of Eli Lilly and Company in the fourth quarter worth approximately $25,000. Basso Capital Management L.P. purchased a new position in shares of Eli Lilly and Company during the fourth quarter valued at approximately $30,000. Maseco LLP boosted its position in shares of Eli Lilly and Company by 466.7% during the first quarter. Maseco LLP now owns 34 shares of the company's stock valued at $31,000 after buying an additional 28 shares during the last quarter. Gunpowder Capital Management LLC dba Oliver Wealth Management purchased a new position in shares of Eli Lilly and Company during the fourth quarter valued at approximately $39,000. Finally, Aventus Investment Advisors Inc. grew its holdings in Eli Lilly and Company by 270.0% during the first quarter. Aventus Investment Advisors Inc. now owns 37 shares of the company's stock worth $34,000 after buying an additional 27 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Wall Street Analysts Forecast Growth

LLY has been the subject of a number of analyst reports. Guggenheim increased their price target on Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the company a "buy" rating in a research report on Friday, September 18th. JPMorgan Chase & Co. raised their price objective on Eli Lilly and Company from $1,400.00 to $1,500.00 and gave the company an "overweight" rating in a research note on Monday, September 28th. HSBC lifted their price objective on shares of Eli Lilly and Company from $850.00 to $940.00 and gave the stock a "reduce" rating in a report on Thursday, September 10th. Bank of America upped their target price on shares of Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a "buy" rating in a research note on Friday, July 10th. Finally, BMO Capital Markets reiterated an "outperform" rating on shares of Eli Lilly and Company in a report on Thursday, October 1st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $1,313.43.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $1,211.08 on Thursday. Eli Lilly and Company has a twelve month low of $783.85 and a twelve month high of $1,292.65. The stock's 50 day moving average price is $1,177.42 and its 200-day moving average price is $1,104.28. The company has a market capitalization of $1.14 trillion, a PE ratio of 40.64, a PEG ratio of 1.50 and a beta of 0.46. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, beating analysts' consensus estimates of $6.40 by $1.98. The company had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. Eli Lilly and Company's revenue was up 47.7% on a year-over-year basis. During the same period last year, the business posted $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, equities analysts anticipate that Eli Lilly and Company will post 34.79 EPS for the current year.

Insiders Place Their Bets

In other news, EVP Anat Hakim sold 5,000 shares of the firm's stock in a transaction on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the sale, the executive vice president directly owned 11,875 shares of the company's stock, valued at $14,131,250. This trade represents a 29.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the sale, the chief accounting officer owned 1,526 shares in the company, valued at $1,808,325.26. The trade was a 56.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 13,500 shares of company stock valued at $15,958,170. Insiders own 0.14% of the company's stock.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analysts at Erste Group raised their FY2026 EPS estimate to $36.55 from $36.45 and their FY2027 forecast to $47.30 from $47.18, reinforcing expectations for continued profit growth above consensus. Analyst earnings estimates
• Positive Sentiment: Investor commentary continues to highlight Lilly’s dominant position in diabetes and obesity treatments, strong revenue growth and a pipeline that could support further expansion beyond Zepbound. Retatrutide is viewed as a particularly important future growth opportunity ahead of the company’s October 29 earnings report. Retatrutide earnings outlook
• Positive Sentiment: Lilly is collaborating with Prelude Therapeutics to test the experimental breast-cancer drug PRT13722 in combination with established therapies. Enrollment is expected to begin in the fourth quarter, adding potential long-term oncology value to Lilly’s pipeline. Prelude and Lilly breast cancer collaboration
• Positive Sentiment: Broader oncology spending is projected to exceed $400 billion globally by 2028, creating an attractive market backdrop for Lilly’s cancer-drug development and partnerships. Cancer drug spending outlook
• Neutral Sentiment: A Phase 1 food-effect study for tersolisib represents incremental pipeline progress, but the early-stage trial is unlikely to materially affect near-term earnings or valuation. Tersolisib study update
• Negative Sentiment: Valuation remains a concern after a roughly 404% five-year rally. Lilly trades at a high earnings multiple, so the stock may need sustained obesity-drug growth and successful pipeline launches to justify its price. Investors also face near-term volatility around the upcoming earnings release and clinical data.
• Negative Sentiment: A combination treatment generated greater weight loss than Zepbound in reported findings, but discontinuation rates were substantially higher, highlighting potential tolerability and adherence challenges for next-generation obesity therapies. Obesity-drug combination results

Eli Lilly and Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer's disease.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.